Submit a Letter to the Editor for:
Fumito Ichinose, Roman Ullrich, Adam Sapirstein, Rosemary C. Jones, Joseph V. Bonventre, Charles N. Serhan, Kenneth D. Bloch, Warren M. Zapol
J Clin Invest. 2002;
109(11):1493
doi:10.1172/JCI14294
Abstract |
Full text
|
PDF
C
ytosolic phospholipase A2 (cPLA2) releases arachidonic acid (AA) from phospholipids in cell membranes. To assess the role of cPLA2 in hypoxic pulmonary vasoconstriction (HPV), we measured the increase in left lung pulmonary vascular resistance (LPVR) before and during hypoxia produced by left main stem bronchus occlusion (LMBO) in mice with and without a targeted deletion of the PLA2g4a gene that encodes cPLA2α. LMBO increased LPVR in cPLA2α+/+ mice but not in cPLA2α–/– mice. cPLA2α+/+ mice were better able to maintain systemic oxygenation during LMBO than were cPLA2α–/– mice. Administration of a cPLA2 inhibitor, arachidonyl trifluoromethyl ketone, blocked the LMBO-induced increase in LPVR in wild-type mice, while exogenous AA restored HPV in cPLA2α–/– mice. Intravenous angiotensin II infusion increased PVR similarly in cPLA2α+/+ and cPLA2α–/– mice. Inhibitors of cyclooxygenase or nitric oxide synthase restored HPV in cPLA2α–/– mice. Breathing 10% oxygen for 3 weeks produced less right ventricular hypertrophy in cPLA2α–/– than in cPLA2α+/+ mice, but restored HPV in cPLA2α–/– mice despite the continued absence of cPLA2 activity. These results indicate that cPLA2 contributes to the murine pulmonary vasoconstrictor response to hypoxia. Augmenting pulmonary vascular tone restores HPV in the absence of cPLA2 activity.
Guidelines:
The Editorial Board will only consider letters that we deem relevant and of interest to our readers. We will not post data that have not been subjected to peer review, nor will we post letters that are essentially a reiteration of another letter. All accepted letters will be posted on our website within one week of acceptance. The Editors reserve the right to edit any letter for length, content, and clarity. Authors of all accepted letters will be asked to preview any changes. Authors will be notified by e-mail if their letters were not accepted. As this is a final decision, no appeals will be considered.
Specific requirements: All letters must be 400 words or fewer. You may enter the letter as plain text or HTML, if you wish. The author's name and e-mail address are required, and will be posted with the letter. All possible conflicts of interest must be noted, even if they are not posted. If you wish to include a figure (keep in mind that non-peer-reviewed data will not be posted), please contact the editor directly at editors@the-jci.org.
